Advertisement
Australia markets close in 3 hours 27 minutes
  • ALL ORDS

    7,942.80
    +45.30 (+0.57%)
     
  • ASX 200

    7,673.00
    +44.00 (+0.58%)
     
  • AUD/USD

    0.6619
    +0.0007 (+0.10%)
     
  • OIL

    78.43
    +0.32 (+0.41%)
     
  • GOLD

    2,318.80
    +10.20 (+0.44%)
     
  • Bitcoin AUD

    96,878.50
    +1,147.73 (+1.20%)
     
  • CMC Crypto 200

    1,334.42
    +57.44 (+4.50%)
     
  • AUD/EUR

    0.6146
    +0.0006 (+0.09%)
     
  • AUD/NZD

    1.1019
    +0.0027 (+0.24%)
     
  • NZX 50

    11,835.75
    -102.33 (-0.86%)
     
  • NASDAQ

    17,890.79
    +349.29 (+1.99%)
     
  • FTSE

    8,213.49
    +41.34 (+0.51%)
     
  • Dow Jones

    38,675.68
    +449.98 (+1.18%)
     
  • DAX

    18,001.60
    +105.10 (+0.59%)
     
  • Hang Seng

    18,444.76
    -31.16 (-0.17%)
     
  • NIKKEI 225

    38,236.07
    -38.03 (-0.10%)
     

Company News for Apr 18, 2024

  • Eli Lilly and Company (LLY) shares rose 0.5% after announcing positive late-stage results for its weight-loss drug Zepbound, which is especially beneficial for overweight individuals with sleep apnea.

  • Shares of Autodesk, Inc. (ADSK) fell 5.8% following news of a delay in the filing of its annual Form 10-K due to an internal investigation into its accounting practices related to free cash flow and adjusted operating margin.

  • Mobileye Global Inc. (MBLY) increased 2.8% after announcing the delivery of its new EyeQ6 Lite system-on-chip, accelerating ADAS upgrades globally.

  • U.S. Bancorp (USB) shares tumbled 3.6% after reporting first-quarter 2024 revenues of $6.69 billion, missing the Zacks Consensus Estimate by 0.16%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Eli Lilly and Company (LLY) : Free Stock Analysis Report

U.S. Bancorp (USB) : Free Stock Analysis Report

Autodesk, Inc. (ADSK) : Free Stock Analysis Report

Mobileye Global Inc. (MBLY) : Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research